How are RAPP straddle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the RAPP straddle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 74.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$2,031.74 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a RAPP straddle?

The breakeven for the RAPP straddle priced on this page is roughly $27.15 and $67.85 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The RAPP market-implied 1-standard-deviation expected move in the same options snapshot is approximately 21.39%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current RAPP implied volatility affect this straddle?

RAPP ATM IV is at 74.60% with IV rank near 14.86%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

RAPP Straddle Strategy

RAPP (Rapport Therapeutics, Inc. Common Stock), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.

RAPP (Rapport Therapeutics, Inc. Common Stock) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $2.28B, a beta of 0.97 versus the broader market, a 52-week range of 13.86-49.5, average daily share volume of 357K, a public-listing history dating back to 2024, approximately 84 full-time employees. These structural characteristics shape how RAPP stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.97 places RAPP roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.

What is a straddle on RAPP?

A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.

RAPP snapshot

As of August 14, 2026, spot at $47.29, ATM IV 74.60%, IV rank 14.86%, expected move 21.39%. The straddle on RAPP below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 98-day expiry.

Why this straddle structure on RAPP specifically: RAPP IV at 74.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a RAPP straddle, with a market-implied 1-standard-deviation move of approximately 21.39% (roughly $10.11 on the underlying). The 98-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated RAPP expiries trade a higher absolute premium for lower per-day decay. Position sizing on RAPP should anchor to the underlying notional of $47.29 per share and to the trader's directional view on RAPP stock.

RAPP straddle setup

The RAPP straddle below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With RAPP at $47.29 on that close, the first option leg uses a $47.50 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed RAPP chain at a 98-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 RAPP shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$47.50	$10.25
Buy 1	Put	$47.50	$10.10

RAPP straddle risk and reward

Net Premium / Debit: -$2,035.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$2,031.74
Breakeven(s): $27.15, $67.85
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.

RAPP straddle payoff curve

Modeled P&L at expiration across a range of underlying prices for the straddle on RAPP. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$2,714.00
$10.46	-77.9%	+$1,668.50
$20.92	-55.8%	+$623.01
$31.37	-33.7%	-$422.49
$41.83	-11.5%	-$1,467.99
$52.28	+10.6%	-$1,556.51
$62.74	+32.7%	-$511.02
$73.19	+54.8%	+$534.48
$83.65	+76.9%	+$1,579.98
$94.10	+99.0%	+$2,625.48

When traders use straddle on RAPP

Straddles on RAPP are pure-volatility plays that profit from large moves in either direction; traders typically buy RAPP straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.

RAPP thesis for this straddle

The market-implied 1-standard-deviation range for RAPP extends from approximately $37.18 on the downside to $57.40 on the upside. A RAPP long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current RAPP IV rank near 14.86% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on RAPP at 74.60%. As a Healthcare name, RAPP options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to RAPP-specific events.

RAPP straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. RAPP positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move RAPP alongside the broader basket even when RAPP-specific fundamentals are unchanged. Always rebuild the position from current RAPP chain quotes before placing a trade.

Frequently asked questions

What is a straddle on RAPP?: A straddle on RAPP is the straddle strategy applied to RAPP (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With RAPP stock at $47.29 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed RAPP chain strike and the premiums come straight from that session's bid/ask midpoint.
How are RAPP straddle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the RAPP straddle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 74.60%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$2,031.74 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a RAPP straddle?: The breakeven for the RAPP straddle priced on this page is roughly $27.15 and $67.85 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The RAPP market-implied 1-standard-deviation expected move in the same options snapshot is approximately 21.39%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a straddle on RAPP?: Straddles on RAPP are pure-volatility plays that profit from large moves in either direction; traders typically buy RAPP straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
How does current RAPP implied volatility affect this straddle?: RAPP ATM IV is at 74.60% with IV rank near 14.86%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.